Article
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Breast cancer research and treatment - 1 Jul 2013
Dezentjé V O, van Schaik R H N, Vletter-Bogaartz J M, van der Straaten T, Wessels J A M, Kranenbarg E M-K, Berns E M, Seynaeve C, Putter H, van de Velde C J H, Nortier J W R, Gelderblom H, Guchelaar H-J
Abstract excerpt
The clinical importance of CYP2D6 genotype as predictor of tamoxifen efficacy is still unclear. Recent genotyping studies on CYP2D6 using DNA derived from tumor blocks have been criticized because loss of heterozygosity (LOH) in tumors may lead to false genotype assignment. Postmenopausal early breast cancer patients who were randomized to receive tamoxifen, followed by exemestane in a large randomized controlled...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.